EXORPHIA and Rohto Pharmaceutical's Strategic Collaboration
In an exciting development for the healthcare and regenerative medicine sectors, EXORPHIA, a pioneering startup based in Tokyo, has announced a capital and business alliance with Rohto Pharmaceutical, headquartered in Osaka. This strategic partnership aims to leverage the strengths of both companies to advance the research and production technologies of extracellular vesicles (EVs).
Background of the Partnership
Founded in 2019, EXORPHIA specializes in creating innovative medical solutions utilizing EVs, which are essential in facilitating cell-to-cell communication by transporting biologically active substances, such as proteins and nucleic acids. The startup has worked diligently on product development across various disease areas since its inception.
Rohto Pharmaceutical, with a legacy dating back to 1949, embraces a vision to enhance well-being through diverse healthcare initiatives. They have outlined their aspirations for the future of healthcare in their *
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.